麻豆传媒

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.

Bota is co-director of the UCI Health Comprehensive Brain Tumor Program and is a lead investigator on several clinical trials, including novel treatments using brain tumor vaccines and the use of electrical fields to inhibit the growth of gliomas.

---

Dr. Lakshmi Nayak serves as Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston. She is an Associate Professor of Neurology at Harvard Medical School. She received her medical degree at Grant Medical College in Mumbai, India. She completed her residency at New York Presbyterian Hospital/ Cornell, and fellowship at Memorial Sloan-Kettering Cancer Center in New York. Her research includes development of novel therapies through preclinical and clinical studies for management of primary brain tumors including glioblastoma and primary central nervous system lymphoma, with particular focus on molecular targeted agents and immunotherapeutics, including CAR T-cell therapy.  She leads the international neurologic assessment in neuro-oncology (NANO) effort for evaluation of neurologic function in patients with brain tumors. 

Gilbert Youssef, MD is Neuro-Oncologist at Dana-Farber Cancer Institute.  He primarily treats patients with brain and spinal cord tumors, including, glioma, meningioma, ependymoma, medulloblastoma, schwannoma, lymphoma, and brain metastases.  He also treats patients who develop neurologic complications from cancer or its treatment.
He is interested in neuroimaging, while focusing on clinical endpoints in clinical trials.  He is also involved in multiple clinical trials that are ongoing at Dana-Farber.

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.




 

The diagnosis of cancer is incredibly difficult for anyone, but when it’s your child, it’s particularly devastating. I make sure to reassure patients, parents, families and caregivers that this is a partnership and a journey we will weather together. Part of my job is to teach them about the tumor, the treatment, and expected side effects of that treatment, but what they don’t initially realize is how much they will teach me in return. I’ve had years of training to prepare for this; they have had but a few weeks. Yet one of the most rewarding parts of my job is to watch my patients, their families and caregivers transition from students to teachers. I think it’s important to also acknowledge that although we may not cure every patient with a brain tumor, we will help patients to live as long and as well as possible with current therapies and supportive care.